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Abstract
Objective: The objective of this study is to evaluate the efficacy of adjuvant interferon therapy for hepatitis B
virus-related hepatocellular carcinoma (HCC) after different previous therapy.
Methods: An electronic search for articles about adjuvant treatment with IFN for patients with HCC published
between 2000 and 2015 was conducted in MEDLINE, PubMed, Cochrane Library, and EMBASE databases. All
data was tested with Stata12.0 software.
Results: Six trials with a total of 1054 subjects were screened according to inclusion and exclusion standards.
Five hundred and seventeen HCC patients were treated with adjuvant treatment with IFN and 537 patients
with placebo. Compared to the control group, both the recurrence rate and death rate of HCC in IFN group
were statistically lower, especially after transhepatic arterial chemotherapy and embolization (TACE) treatment
and both TACE and resection according to subgroup analysis.
There is no statistical significance on the both recurrence and death rate of HBV-related hepatocellular carcinoma after
surgical resection treatment (RR = 0.96, 95 % CI, 0.84 to 1.1, p = 0.59 for recurrence and RR = 0.78, 95 % CI, 0.60 to 1.04,
p = 0.09 for death rates).
Conclusions: Adjuvant IFN therapy may significantly reduced mortality as well as recurrence rate of patients with
HBV-related HCC after no matter what the previous treatment. On the other hand, there is no statistical significance
on the recurrence rate and mortality after surgical resection only. More research is needed into the relationship
between effect of adjuvant interferon therapy and previous therapy, especially TACE.
Background
Primary liver cancer is mainly composed of hepatocellu-
lar carcinoma (HCC), which is the world’s third most
common cause of cancer deaths [1]. About 55 % liver
cancer deaths worldwide occur in China, because of the
highest age-adjusted incidence of HCC due to chronic
hepatitis B (CHB) [2]. Due to the high difficulty in early
diagnosis of malignant tumors, most of cancer metasta-
sis have occurred for the first time seeing a doctor [3].
Most patients received surgical resection or transhepatic
arterial chemotherapy and embolization (TACE) [4]. Un-
fortunately, the recurrence rate after 3 years of liver can-
cer which is treated by pure resection or chemotherapy
via hepatic artery embolism is more than 50 %, which is
the main cause of death after treatment [5, 6]. Most
HCC patients carry with hepatitis virus, which is one of
the three main complications of patients with CHB,
resulting in one million deaths each year [6, 7] and, of
these, nearly 500,000 deaths are in China [2]. Studies
have suggested interferon can reduce the recurrence of
HCC after treatment, because interferon can inhibit the
replication of the hepatitis virus and kill cancer cells, but
the conclusion is not consistent [8–11].
In this paper, the clinical data is put forward by
evidence-based medicine system evaluation, and a
meta-analysis using fixed/random effects model is
used to study the influence of recurrence rate and
mortality of viral hepatitis liver cancer, which is
treated by interferon after surgical resection or TACE
or both surgical resection and TACE, and provide the
foundation for evidence-based medicine.
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We reviewed all the experimental results of the curative ef-
fect of interferon adjuvant treating patients with HCC.
Computerized literature searches of PubMed, the Cochrane
Library, and EMBASE database (2005–2015) were under-
taken. Search words were “hepatocellular carcinoma,” “liver
cancer,” “liver tumor,” “interferon.” Review was conducted
with these terms separately in different combinations. In
addition, references catalog of relevant original articles and
comments were reviewed to find out other qualified trials.
Inclusion and exclusion criteria
The inclusion criteria are as follows: (1) All the cases
were pathologically diagnosed as liver cancer combined
with viral-B hepatitis; (2) both interferon group and con-
trol group were treated by surgical removal or TACE; (3)
the interferon adjuvant therapy was given after the first
treatment (surgical removal, TACE) for more than
3 months; (4) the follow-up time must be more than
1 year, and the control group was treated with placebo;
and (5) the sample size >35.
The exclusion criteria are as follows: (1) Metastatic
liver cancer or recurrent liver cancer has been treated;
(2) repetitive articles and small proportion articles; (3)
the follow-up time was less than 1 year; and (4) the sam-
ple size <35.
Data extraction
Two reviewers independently extracted all literatures to de-
termine if the relevant trials meet the included criteria.
The study incorporated is reviewed by random
method, blinded method, and follow-up distribution
plan. According to the Cochrane system evaluation
handbook, the creditability of all studies can be di-
vided into three levels (Table 1).
Data analysis
The review management software (Stata) is used for statis-
tical analysis, and all outcomes were expressed as RR with
95 % CI. The Cochrane Q test was used to detect hetero-
geneity of the effects; significant heterogeneity was defined
as a p value <0.1. A fixed effects model or random effects
model was used depending on the absence or presence of
heterogeneity. I2 statistic was estimated to describe the
percentage of the variability attributable to heterogeneity.
Studies with an I2 statistic of <25 % are considered to have
no heterogeneity, those with an I2 statistic of 25–50 % are
considered to have low heterogeneity, and those with an I2
statistic of 50–75 % are considered to have moderate het-
erogeneity, in which the random effects model was used.
Retrieval results
Two hundred and nineteen relevant articles were re-
trieved through combined manual and computerized re-
trieval in the MEDLINE, PubMed, the Cochrane Library,
and EMBASE database from 2005–2015. One hundred
and thirty-six articles were excluded, because the title
and abstract has nothing to do with the purpose of this
meta-analysis. Finally, 6 articles and a total of 1054 sub-
jects were included in the systematic review, including 4
randomized controlled trials and 2 nonrandomized con-
trolled trials.
Four trials examined the effect of IFN after surgical re-
section and one trial after TACE only and the other after
both surgical resection and TACE.
A total of 1054 subjects were included in the final
meta-analysis: including 517 HCC patients who were
treated with interferon and 537 patients who were
treated with placebo. The longest follow-up period was
85.2 months, and the shortest follow-up period was
24.0 months. The maximum sample size was 126, and
the minimum sample size was 35. Characteristics of the
6 included studies were listed in Table 2.
Meta-analysis
We compare the recurrence rate and mortality between
TACE and hepatic resection (HR), both TACE and HR
in the treatment of HCC. For further testing differences
of the recurrence rate and mortality of different kinds of
treatment, we process the subgroup analysis according
to the different types of treatment. The meta-analysis re-
sults were shown in Fig. 1.
Recurrence of hepatocellular carcinoma
Six articles [10–15], including 1054 patients, compared
the recurrence of hepatocellular carcinoma in the inter-
feron group and the control group. We used “RR” as an
Table 1 Quality of assessment of each included studies
Study Trial type Random sample Allocation concealment Blinded allocation Lost of follow-up ITT Grade
Lo CM RCT Adequate Adequate Unclear Yes Yes A
Li M RCT Adequate Unclear Unclear Yes Yes B
Li N nRCT Adequate Adequate Unclear Yes Yes B
Sun HC RCT Adequate Adequate Adequate Yes Yes A
Chen LT RCT Adequate Adequate Adequate Yes Yes A
Chao Zou nRCT Adequate Adequate Adequate Yes Yes A
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indicator of testing method of therapeutic effect and
used X2 test to examine heterogeneity, and the result
was p = 0.72 (>0.10), I2 = 0 % (<50 %), which suggested
no heterogeneity between the two groups. The fixed ef-
fects model was used for meta-analysis. Results (RR =
0.90, 95 % CI, 0.83 to 0.99, p = 0.02) showed that inter-
feron adjuvant therapy can significantly reduce the re-
currence rate of HCC after initial treatment, especially
after TACE treatment and both TACE and surgical
resection treatment according to subgroup analysis
(RR = 0.80, 95 % CI, 0.65 to 0.99, p = 0.04 for TACE;
and RR = 0.87, 95 % CI, 0.78 to 0.98, p = 0.02 for both
TACE and surgical resection). Pooled data analysis
revealed that the interferon group had no statistical
significance on the recurrence of HBV-related hepato-
cellular carcinoma after surgical resection treatment
(RR = 0.96, 95 % CI, 0.84 to 1.1, p = 0.59).
Death rates for hepatocellular carcinoma
Something similar seems to be happening in death rate.
With the same articles, we compared the death rate of he-
patocellular carcinoma in the interferon group and the con-
trol group. The result was p = 0.67 (>0.10), I2 = 51.4 %
(>50 %), and the unfixed effects model was used for meta-
analysis. The death rate in the IFN group also significantly
decreased according to not only total event analysis (RR =
0.72, 95 % CI, 0.60 to 0.87, p = 0.001) but also subgroup
analysis (RR = 0.75, 95 % CI, 0.63 to 0.90, p = 0.002 for both
TACE and surgical resection; and RR = 0.56, 95 % CI, 0.43
to 0.73, p = 0.000 for TACE). But, as well, there is no statis-
tical significance on the mortality of HBV-related hepato-
cellular carcinoma after surgical resection treatment (RR =
0.78, 95 % CI, 0.60 to 1.04, p = 0.09).
Sensitivity analysis and publication bias
Testing each indicator with fixed/random effects model
and visual inspection of chart of sensitivity (Fig. 2), we
found that the results are related to each other. We
made a funnel chart to compare the including subgroups
(Fig. 3). The characteristic of the two funnel charts was
basically an inverted funnel and bilateral symmetry,
which indicated that there was no publication bias and
the conclusion is reliable.
(Begg’s test statistic, p = 0.45; Egger’s test statistic, p =
0.52 for the funnel plots of recurrence; Begg’s test statis-
tic, p = 0.71; Egger’s test statistic, p = 0.98 for the funnel
plots of death rates.)
Discussion
HCC is the third leading cause of cancer-related deaths
worldwide [1], which has one of the most common risk
factors, HBV [16, 17], especially in Asian countries where
HBV has a higher incidence [18]. Eighty-five to ninety per-
cent of HCC contain HBV-DNA-integrated tumor cells,
providing the strongest evidence for HBV-DNA integra-
tion being the primary etiology of CHB-related HCC [19].
Hepatic resection or liver transplantation may provide a
complete cure for HCC. However, postoperative recur-
rence is a big concern [20]. Most recurrences occur within
1 year after surgery. HCC recurrence rate is also relatively
high in patients who had liver transplantations [21].
In clinical work, the main method of treatment of liver
cancer is surgery and TACE [22]. In order to eliminate
deviation caused by different treatment methods, this
paper chose the surgery, TACE, and both TACE and sur-
gery resection to treat liver cancer and determined the
difference between the two methods through subgroup
analysis. The results showed that both the recurrence
Table 2 Details of included studies
Author/Ref. Year/country Previous therapy Group No. Median age Gender (M:F) Interventions Median follow-up time (m)
Chao Zou 2015 Resection + TACE IFN 102 53 91:11 IFN –
Control 126 52 113:13 IFN + TACE.
Li N 2010 Resection IFN 43 53.2 31:12 IFN –
Control 36 51.2 26:10 ST
Sun, HC 2006 China Resection IFN 118 52.2 106:12 IFN 36.5
Control 118 50.4 102:16 ST
Lo, CM 2007 China Resection IFN 40 49 31:9 IFN Minimum follow-up 30
Control 40 54 34:6 ST
Li, MQ 2009 China TACE IFN 108 NA 77:31 IFN 24.8
Control 108 NA 74:34 ST
Chen, LT 2012 China Resection IFN 133 NA 108:25 IFN 63.8 (60.8–66.9)
Control 135 NA 112:23 ST
TACE transarterial chemoembolization, ST symptomatic treatment
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Fig. 1 Forest plot of the effect of adjuvant IFN. a The comparison between IFN group and control group in the recurrence rates of HCC. b The
comparison between IFN and control group in the death rates of HCC. Abbreviation: IFN interferon, TACE transarterial chemoembolization. Summary
RRs are shown as diamonds, with the middle corresponding to the point estimate and the width representing the 95 % CI
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Fig. 2 Chart of sensitivity for each comparisons. a Recurrence rate of HCC. b Death rates of HCC
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Fig. 3 Funnel plot for each comparison. a Recurrence rate of HCC. b Death rates of HCC
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and mortality of liver cancer had significant differences
between interferon group and the control group. But,
there is no statistical significance on the recurrence rate
and mortality of HBV-related hepatocellular carcinoma
after surgical resection only. This result was contrary to
the meta-analyses or systematic reviews published before
[23]. One of the meta-analysis reported by Zhang in-
cluded one trial less than ours. And, this trial [15] was
published recently by Zuo, and its conclusion was con-
trary to the trials which were included in Zhang’s report.
Meanwhile, samples in Zuo’s report were larger than any
other RCTs [10–15], which were all included in our
meta-analysis. So, the weight of the trial largely affected
the final results, different conclusion achieved is reason-
able. Still, it is worth noting that the added article is a
nRCT.
Interferon has many biological functions, such as anti-
viral, antiproliferative, antiangiogenic, and immunomod-
ulatory effects, and it is widely used in the treatment of
various diseases [24, 25]. In vitro experiments showed
that [26] alpha interferon can inhibit the proliferation of
endothelial cells of human umbilical vein, and its inhib-
ition function increased with dose and time increased.
In vivo experiments showed that [27] tumor diameter is
decreased obviously after adjuvant therapy with inter-
feron, and microvascular density was obviously lower
than the control group, and there was significant differ-
ence. So, it is presumable that alpha interferon realizes
its antitumor effect by inhibiting tumor angiogenesis
and anticell proliferation. The above biological charac-
teristics can explain the interferon adjuvant therapy is
beneficial for the treatment of liver cancer.
On the other hand, some studies found that the effi-
cacy of IFN on inducing hepatitis Be antigen (HBeAg)
seroconversion is not so good [28] and the sustained vi-
rologic response rate was only 25 % [29]. But, the main
effects of interferon are antiviral, immune regulation,
and antiproliferative agents rather than the integration
of HBV gene inhibitors [30]. Interferon treatment im-
proves liver fibrosis and liver function by reducing active
hepatitis [31], and it can improve overall survival by re-
ducing the severity of the recurrence of the tumor, so it
is suitable for secondary therapeutic ablation or resec-
tion [32]. From the above description, we can draw the
conclusion: interferon does not prevent HBV-related
HCC, but there is still a long-term effective effect for
viral hepatitis-related HCC.
Several limitations of this study should be considered:
(1) Although most of the studies are randomized con-
trolled trials, the sample sizes are relatively small; (2) the
basic characteristics of included cases were not identical,
and the effect factors (including the clinical stages, patho-
logical pattern, therapeutic method, the size of the tumor,
and the body’s immune ability), which influenced clinical
prognosis of hepatocellular carcinoma, may affect the re-
sults of the meta-analysis; and (3) the included studies
mostly reported the recurrence rate and mortality, but
there are less reports on overall survival rate and disease-
free survival (DFS) of interferon adjuvant therapy.
Conclusions
In short, the meta-analysis, which included six literatures,
indicated that interferon adjuvant therapy can significantly
reduce the recurrence rate of viral hepatitis-related hepa-
tocellular carcinoma and improve the survival rate of pa-
tients after no matter previous treatment is given
including surgical resection and TACE. On the other
hand, there is no statistical significance on the recurrence
rate and mortality of HBV-related hepatocellular carcin-
oma after surgical resection only. More research is needed
into the relationship between effect of adjuvant interferon
therapy and previous therapy, especially TACE.
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